12 High Growth Large Cap Stocks to Buy Now

1) Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

5-Year Revenue Growth: ~35.0%

Average Upside Potential: ~72.6%

Market cap as of 12 November: $11.06 billion

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a commercial-stage biopharmaceutical company, which is focused on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for treating rare diseases.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s flagship product, Elevidys, received expanded approval from the U.S. FDA, placing the company as a dominant player in the DMD treatment market. Elevidys exhibited statistically significant effects on secondary endpoints reflective of muscle function in clinical trials, catering to a critical unmet need in DMD treatment. One key challenge that is being faced by Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is ensuring sufficient manufacturing capacity to meet the expected high demand for Elevidys.

The company focuses on addressing this by transitioning to suspension manufacturing by around 2026, which is expected to fuel production capacity. Beyond Elevidys and the DMD market, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) possesses several avenues for future growth such as Exon-Skipping Therapies and mergers and acquisitions. The successful long-term data from ongoing studies might further strengthen Elevidys’ position as the standard of care for DMD. This will result in even broader adoption and use in younger patients.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s gene therapy portfolio for Limb-Girdle Muscular Dystrophy provides a strong opportunity for diversification and growth. With SRP-9003, the company should become a key leader in another rare disease space. The total revenues rose by $135.4 million in Q3 2024 compared to the same period of 2023. The increase stemmed from the initial product launch of ELEVIDYS in June 2023 and the expanded label in June 2024.

Royal Bank of Canada reaffirmed an “Outperform” rating on the shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT), setting a price objective of $182.00 on 21^st October.

While we acknowledge the potential of SRPT as an investment, our conviction lies in the belief that some deeply undervalued AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for a deeply undervalued AI stock that is more promising than SRPT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.